tetano
Editor, Senior Moderator
Biomed Hub
. 2021 Dec 8;6(3):145-152.
doi: 10.1159/000519565. eCollection Sep-Dec 2021.
Covid-19 Impact on Macular Neovascularization and Retinal Vein Occlusion Treatment: Single-Center Experience
Rodrigo Vilares-Morgado[SUP] 1 2 3 [/SUP], Carolina Madeira[SUP] 1 [/SUP], Ana Maria Cunha[SUP] 1 [/SUP], Manuel Falcão[SUP] 1 2 3 [/SUP], João Beato[SUP] 1 [/SUP], Ana Catarina Pedrosa[SUP] 1 3 [/SUP], Susana Penas[SUP] 1 3 [/SUP], Elisete Brandão[SUP] 1 3 [/SUP], Fernando Falcão-Reis[SUP] 1 2 3 [/SUP], Ângela Carneiro[SUP] 1 2 3 [/SUP]
Affiliations
Abstract
Purpose: The aim of this study was to evaluate whether the coronavirus disease 19 (COVID-19) pandemic resulted in undertreatment and subsequent loss of visual acuity (VA) in patients with macular neovascularization (MNV) or retinal vein occlusion (RVO) regularly treated with intravitreal antivascular endothelial growth factor injections.
Methods: Single-center, retrospective study of patients scheduled for treatment between March 19 and June 1, 2020, the national mandatory quarantine period. Patients' demographics, VA, and scheduled treatment during this period were reviewed via medical records. All patients were analyzed regarding treatment attendance rates. The visual impact of COVID-19 was assessed in patients who had been treated and presented a stable VA for >6 months before the beginning of the quarantine.
Results: This study included 927 eyes from 769 patients. The attendance rate increased throughout the study timeframe (p < 0.001) and correlated negatively with higher patient's age (r = -0.142; p = 0.005). Patients with age-related macular degeneration (67.6%) had lower attendance rates (p = 0.007) and were older (p < 0.001). The visual impact analysis included 400 eyes from 325 patients. The average VA variation throughout this period was -1.7 ± 8.4 ETDRS letters and was similar in different retinal pathologies (p = 0.334). VA variation did not correlate with the number of missed treatments per patient (r = 0.100; p = 0.150). The prevalence of subretinal fluid and intraretinal fluid, as well as central retinal thickness decreased significantly throughout the study period (p values of <0.001, <0.001, and 0.032, respectively).
Conclusion: The COVID-19 pandemic had a significant impact on the attendance rate of patients with MNV or RVO to their scheduled treatments, which was higher in the first week of mandatory quarantine. Nevertheless, VA did not decrease significantly during this period, with a limited VA variation regardless of primary retinal disorder and morphological parameters even improved in the eyes included in the visual impact analysis.
Keywords: Antivascular endothelial growth factor treatment; COVID-19; Macular neovascularization; Retinal vein occlusion.
. 2021 Dec 8;6(3):145-152.
doi: 10.1159/000519565. eCollection Sep-Dec 2021.
Covid-19 Impact on Macular Neovascularization and Retinal Vein Occlusion Treatment: Single-Center Experience
Rodrigo Vilares-Morgado[SUP] 1 2 3 [/SUP], Carolina Madeira[SUP] 1 [/SUP], Ana Maria Cunha[SUP] 1 [/SUP], Manuel Falcão[SUP] 1 2 3 [/SUP], João Beato[SUP] 1 [/SUP], Ana Catarina Pedrosa[SUP] 1 3 [/SUP], Susana Penas[SUP] 1 3 [/SUP], Elisete Brandão[SUP] 1 3 [/SUP], Fernando Falcão-Reis[SUP] 1 2 3 [/SUP], Ângela Carneiro[SUP] 1 2 3 [/SUP]
Affiliations
- PMID: 35083227
- PMCID: PMC8740216
- DOI: 10.1159/000519565
Abstract
Purpose: The aim of this study was to evaluate whether the coronavirus disease 19 (COVID-19) pandemic resulted in undertreatment and subsequent loss of visual acuity (VA) in patients with macular neovascularization (MNV) or retinal vein occlusion (RVO) regularly treated with intravitreal antivascular endothelial growth factor injections.
Methods: Single-center, retrospective study of patients scheduled for treatment between March 19 and June 1, 2020, the national mandatory quarantine period. Patients' demographics, VA, and scheduled treatment during this period were reviewed via medical records. All patients were analyzed regarding treatment attendance rates. The visual impact of COVID-19 was assessed in patients who had been treated and presented a stable VA for >6 months before the beginning of the quarantine.
Results: This study included 927 eyes from 769 patients. The attendance rate increased throughout the study timeframe (p < 0.001) and correlated negatively with higher patient's age (r = -0.142; p = 0.005). Patients with age-related macular degeneration (67.6%) had lower attendance rates (p = 0.007) and were older (p < 0.001). The visual impact analysis included 400 eyes from 325 patients. The average VA variation throughout this period was -1.7 ± 8.4 ETDRS letters and was similar in different retinal pathologies (p = 0.334). VA variation did not correlate with the number of missed treatments per patient (r = 0.100; p = 0.150). The prevalence of subretinal fluid and intraretinal fluid, as well as central retinal thickness decreased significantly throughout the study period (p values of <0.001, <0.001, and 0.032, respectively).
Conclusion: The COVID-19 pandemic had a significant impact on the attendance rate of patients with MNV or RVO to their scheduled treatments, which was higher in the first week of mandatory quarantine. Nevertheless, VA did not decrease significantly during this period, with a limited VA variation regardless of primary retinal disorder and morphological parameters even improved in the eyes included in the visual impact analysis.
Keywords: Antivascular endothelial growth factor treatment; COVID-19; Macular neovascularization; Retinal vein occlusion.